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a b s t r a c t 
Each patient’s cancer has a unique molecular makeup, often comprised of distinct cancer cell subpopula- 
tions. Improved understanding of dynamic processes between cancer cell populations is therefore critical 
for making treatment more effective and personalized. It has been shown that immunotherapy increases 
the survival of melanoma patients. However, there remain critical open questions, such as timing and 
duration of immunotherapy and its added beneﬁts when combined with other types of treatments. We 
introduce a model for the dynamics of active killer T-cells and cancer cell subpopulations. Rather than 
deﬁning the cancer cell populations based on their genetic makeup alone, we consider also other, non- 
genetic differences that make the cell populations either sensitive or resistant to a therapy. Using the 
model, we make predictions of possible outcomes of the various treatment strategies in virtual melanoma 
patients, providing hypotheses regarding therapeutic eﬃcacy and side-effects. It is shown, for instance, 
that starting immunotherapy with a denser treatment schedule may enable changing to a sparser sched- 
ule later during the treatment. Furthermore, combination of targeted and immunotherapy results in a 
better treatment effect, com pared to mono-immunotherapy, and a stable disease can be reached with a 
patient-tailored combination. These results offer better understanding of the competition between T-cells 
and cancer cells, toward personalized immunotherapy regimens. 
© 2019 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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0. Introduction 
Each patient’s cancer has a unique molecular makeup, often
omprised of populations of genetically, functionally or epigenet-
cally distinct cancer cell subpopulations that undergo dynamic
volutionary processes throughout the disease course and treat-
ent periods. The goal of making cancer treatment more effec-
ive and personalized therefore requires an improved understand-
ng of such dynamic processes, including evolutionary competition
f space, glucose and other resources between cell populations
hat lead to the survival of ﬁtter populations ( Gillies et al., 2012;∗ Corresponding author at: Vesilinnantie 5, Turku 20500. 
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t
ttps://doi.org/10.1016/j.jtbi.2019.110136 
022-5193/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article ulauche et al., 2018; Greaves, 2015 ). Mathematical modelling of
eterogeneous cell population dynamics and treatment responses
as shown great promise as a means to suggest mono- or combi-
ation therapies that can theoretically control or even inhibit dis-
inct cancer cell populations, as well as provide mechanistic in-
ights into treatment sensitivity and resistance for adaptive inter-
ention designs ( Bozic et al., 2013; Bozic and Nowak, 2014; Fischer
t al., 2015; Louzoun et al., 2014; Michor and Beal, 2015; Zhang
t al., 2017; Zhao et al., 2016 ). However, most of the modelling
orks have focused on genetic differences and architecture of sub-
lones and their evolution, even though also non-genetic differ-
nces between or within tumors are known to contribute to the
ndividual disease course and personalized responses to therapies
n various hematological cancers and solid tumors, including pa-
ients with advanced malignant melanomas. nder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Fig. 1. Presentation of the model as relations between different cell types (T for 
active killer T-cells, C for cancer cells) and resources (R). The other parameters are 
explained in Table 1 . Positive terms increase the density and negative terms de- 
crease the density with the ellipse pointing the affected entity. Cancer cell death 
includes both normal cell death and inhibition caused by targeted treatments and 
chemotherapies. T-cell death includes normal cell death, self-regulation and death 
caused by chemotherapy. Cancer cells consume resources to maintain their prolif- 
erative capacity. Killer T-cells get activated when they encounter cancer cells’ anti- 
gens, but cancer cells can also inhibit T-cell activation by binding their ligands (such 
as PD-L1) to inhibitory receptors on T cell surface (such as PD-1). Lightning bolt ar- 
rows point the relations which are affected by different treatments. The extension 
of the model to multiple cancer cell subpopulations is presented in Supplementary 
Fig. 2. Melanoma is initiated by DNA mutations in melanocytes with
major risk from exposure to ultraviolet light. Melanomas typ-
ically occurs in skin, where it forms lesions of irregular size,
shape and color. In localized disease, common treatment is re-
moval by surgery. However, in the case of advanced malignant
melanoma where the disease has metastasized, multidisciplinary
treatments, such as radiation therapy, targeted therapy (e.g., BRAF
inhibitors such as vemuraﬁnib), chemotherapy (e.g., dacarbazine)
or immunotherapy (e.g., anti-PD-1 such as nivolumab and pem-
brolizumab) are recommended ( Bhatia et al., 2009; Garbe et al.,
2016; Maverakis et al., 2015 ). Novel immunotherapies have greatly
improved the response rate, duration and tumor stability in pa-
tients with advanced melanoma even after treatment discontinu-
ation ( Huang et al., 2019; Topalian et al., 2014 ). However, vary-
ing treatment outcomes persist ( Gauci et al., 2019 ), and despite
the improved clinical beneﬁt, a proportion of patients remain non-
responsive leading to progressive disease ( Robert et al., 2015 ).
In some cases, the treatment has to be repeated periodically to
control the cancer, leading to a chronic disease ( Lipson et al.,
2013 ). However, dormant cancer can also be reached ( Aguirre-
Ghiso, 2007; Ossowski and Aguirre-Ghiso, 2010; Schreiber et al.,
2011; Senft and Ronai, 2016 ), where undetectable cancer persists
after treatment. 
Immune-checkpoint inhibitors are revolutionizing the treatment
of patients with advanced-stage cancers. In particular, the blockade
of programmed cell death protein 1 (PD-1) increases the survival
of patients with metastatic melanoma and other solid tumors. De-
spite encouraging results, however, clinical outcomes of anti-PD-
1 therapy remain highly variable and durable treatment beneﬁt is
limited to a minority of patients ( Keenan et al., 2019 ). Immune-
checkpoint inhibitors reactivate patient’s immune system to defeat
cancer, especially antigen-speciﬁc killer T-cells (or CD8+ T-cells).
Approximately 20–50% of human cancers express programmed
death-ligand (PD-L1) that inhibits the killer T-cell function by bind-
ing to its receptor PD-1 on the T-cell surface ( Chen and Mell-
man, 2013 ). Monoclonal antibodies, such as anti-PD-1, block the in-
activating binding of PD-L1 to its receptor protein PD-1 on killer T-
cell surface, enabling the T-cell to attack the tumor ( Pardoll, 2012 )
(see Supplementary Fig. 1). Additionally, antigen delivery from dy-
ing cancer cells leads to increased activation of killer T-cells that
elevates the regulation of T-cells also by other mechanisms, for ex-
ample T-cell self-regulation. To understand the patient-speciﬁc re-
sponses to immunotherapies, one needs to take into account the
dynamics and competition between active killer T-cells and cancer
cells. Some of the currently unaddressed questions in melanoma
therapy concern the timing of checkpoint blockage, respective ben-
eﬁts of targeted versus checkpoint inhibitors, and how to optimize
the beneﬁt-risk ratio of these regimens ( Robert, 2018 ). 
Immunotherapies are also being tested in combination with
other cancer therapies, including targeted or cytotoxic chemother-
apies, where the former inhibits the growth of cancer cells by in-
terfering with speciﬁc target molecules (e.g., oncogenes), whereas
the latter prevents proliferation of the rapidly proliferating cells
(e.g. traditional chemotherapy). The use of targeted treatments is
preferred as they selectively kill cancer cells harboring a speciﬁc
mutation or other molecular aberration that drives the particu-
lar cancer cell, and therefore they often cause less toxic effects in
noncancerous cells. However, cancer cell populations without the
aberration often remain resistant against the targeted treatment,
and resistant subpopulations may also emerge by new mutations.
For clinical applications, it is important to study the often subtle
balance between the therapeutic eﬃcacy and the degree of side-
effects, especially when modelling the response of chemotherapies
that lead to the death of both cancerous and T-cells. Even though
heavy treatment dosage may potentially kill most cancer cells, the
patient might not tolerate very intense treatment periods. There is need to better understand various treatment choices and their
cheduling, as those currently used in the clinics may not be opti-
al, but rather a result of trial and error or other considerations,
uch as cost issues. 
In the present work, we introduce a comprehensive model
or the dynamics of active killer T-cells and their competition
gainst distinct cancer cell populations under various treatment
odalities, including immunotherapies, targeted and chemothera-
ies. Rather than deﬁning the cancer cell populations based on ge-
etic differences alone, we consider cell populations that are either
ensitive or resistant to a targeted therapy. Using the model, we
ake predictions of possible outcomes of the various treatment
trategies and provide experimentally-testable hypotheses regard-
ng, for example, therapeutic eﬃcacy of treatment schedules (tim-
ng and duration) and toxic effects at different doses. As the ﬁrst
isease model, we chose melanoma, due to its clinical relevance
nd variety of options actually used in melanoma treatment. We
emonstrate the behavior of the model dynamics in several case
tudies that model the effects of anti-PD-1 and targeted therapies,
s well as their combinations, in comparison with chemothera-
ies in virtual melanoma patients characterized by key model pa-
ameters. Our modelling questions focus on the effects of therapy
particularly, targeted, chemo- and immunotherapy) on the cancer
ell populations. In particular, how do patients respond to these
reatments, when using different treatment initiation criteria (Case
tudy 2), durations (Case studies 2, 3 and 4), dosages (Case study
) or combinations (Case studies 3 and 4). 
. Materials and methods 
.1. Model overview 
The dynamics of cancer cells and active killer T-cells are illus-
rated in Fig. 1 for one cancer cell population (see Supplemen-
ary Fig. 2 for multiple cancer subpopulations). Resources R corre-
pond to nutrients, such as glucose, that ﬂow in to and out of the
icroenvironment of cancer being modeled. Cancer cells ( C ) use
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Table 1 
Parameters of the model. Boldfaced parameters are changed in the case corresponding to cancer microenvironment of a virtual melanoma 
patient (see also Tables 2 and 3 ). # T and # C denotes density unit of T-cells and cancer cells as mass/volume and – denotes unitless variables. 
Symbol Value Unit Meaning 
ˆ R 1.5 mass/volume Concentration of resources ﬂowing into the region of interest. 
λ 1 – Relative ﬂow speed of resources. 
s i varies – The proliferation strategy of cancer cell subpopulation i . 
α0 0.1 1/(timeunit 
∗# C ) Lower limit of α( ¯s i ) . 
a 1 1/(timeunit ∗# C ) Upper limit of α( s i ) is α0 + a . 
b 0.5 – The strategy value at which α(s i ) = α0 + a/ 2 
γ 0.8 # C /(mass/volume) Resource usage common to all cancer cells. 
K 8 # C The maximum amount of cancer cells in the region of interest. 
μT 0.5 1/timeunit Normal apoptosis rate of active killer T-cells. 
μi 0.4 1/timeunit Normal apoptosis rate of cancer cell subpopulation i . 
w 0.7 – Maximum proportion at which cancer cells limit each other’s resource 
consumption. 
m varies # T /timeunit Maximum rate of killer T-cell activation. 
u 0.1 # C $$ /timeunit The amount of antigen delivery giving the half maximal activation. 
v 2 – The effect on the slope of h ( d C ) at u . 
αT varies 1/(timeunit ∗# T ) Birth rate of active killer T-cells. 
θ 0.6 – Proportion of active killer T-cells that enter the region of interest. 
 0.015 – The proportion of delivered antigens by one normal cancer cell apoptosis, 
compared with death caused by drugs or killer T-cells. 
ξi varies 1/(timeunit 
∗# T ) Rate at which T-cells kill cancer cell subpopulation i . 
ϕi varies 1/(timeunit 
∗# C ) Rate at which cancer cell subpopulation i makes killer T-cells ineffective. 
δ 0.6 1/(timeunit ∗# T ) Rate of active killer T-cell self-regulation. 
c( τ) varies mass/volume Concentration of a drug at time τ after adding the drug. 
Table 2 
Functions of the model. # T and # C denotes density unit of T-cells and cancer cells as mass/volume; –
denotes unitless variables. 
Symbol Equation Unit Meaning 
α( s i ) Eq. (4) 1/(timeunit 
∗# C ) Resource consumption rate speciﬁc for subpopulation i . 
d C Eq. (8) # C /timeunit The antigen delivery rate by dying cancer at time t . 
h ( d C ) Eq. (9) # T /timeunit Activation of killer T-cells. 
H p Eq. (10) – Hill equation expressing the effect of a cytostatic drug. 
p i Eq. (11) – Killing effect of cytostatic drug on cell type i 
β i Eq. (12) 1/timeunit Killing effect of targeted drug on cell type i . 
ρ i Eq. (13) – Effect of immunotherapy. 
t  
g  
t  
w  
d  
a  
o
 
T  
k  
c  
r  
e  
d  
2
 
f  
T
 
 
S  
n  
d  
t  
s  
b  
a
2
 
o  
t  
T  
e  
p
2
 
t  
s  
r  
o  
s  hese resources to divide. When a cancer cell dies, it delivers anti-
ens, which then cause the activation of killer T-cells ( T ), leading to
he increase in their number. The activated killer T-cells divide as
ell in the microenvironment. Each of the cell types undergo cell
eath caused either by apoptosis or drug treatments. T-cells have
lso self-regulation that is a way of the immune system to prevent
verpopulation of killer T-cells. 
The model parameters are listed in Table 1 and functions in
able 2 . The cell-type speciﬁc proliferation strategy s i is one of the
ey model parameters as it corresponds to the rate at which cancer
ells consume resources to proliferate. The higher the strategy pa-
ameter, the more aggressive is the cancer subpopulation. Param-
ter γ speciﬁes how much one resource unit contributes to cell
ivision, assumed to be equal in all the cancer cell subpopulations.
.2. Model dynamics 
We obtain the following ordinary differential equations (ODEs)
or resources ( R ), cancer cell subpopulations ( C i ) and active killer
-cells ( T ): 
dR 
dt 
= λ( ˆ  R − R ) −
⎛ 
⎝ 1 − w 
∑ 
j 
C j 
1 + ∑ 
j 
C j 
⎞ 
⎠ ∑ 
j 
α( ¯s C j ) RC j (1)
dC i 
dt 
= γα( ¯s C i ) 
⎛ 
⎝ 1 −w 
∑ 
j 
C j 
1 + ∑ 
j 
C j 
⎞ 
⎠ RC i 
⎛ 
⎝ (1 −p i ) 
⎛ 
⎝ 1 −
∑ 
j 
C j 
K 
⎞ 
⎠ −p i 
⎞ 
⎠ 
−μi C i − βi C i − ξi C i θT (2) dT 
dt 
= h (d C ) + (αT (1 − p T ) − μT ) T − αT p T T − δ
2 
T 2 
−
∑ 
i 
(1 − ρi ) ϕ i C i θT . (3) 
These ODEs are explained and justiﬁed in more detail in
ection 2.3 . The Runge–Kutta method (RK45) was used to calculate
umerically the dynamics of ODEs with R version 3.4.4 and RStu-
io version 1.1.453. Parameter values, especially the ones related
o treatments, are altered to obtain multiple situations in the case
tudies corresponding to virtual melanoma patients characterized
y combinations of model parameters. These virtual patient cases
re presented in Section 3 . 
.3. Model details 
This sub-section describes the model in more detail in the form
f ODEs for resources R and each cancer cell subpopulation C i in
he microenvironment of cancer as well as for active killer T-cells
 in the body. A resource-consumer model was used with logistic
quation as the basis of competition between the cancer cell sub-
opulations. 
.3.1. Resources and cancer cells 
Let R denote the concentration of resource (such as glucose) in
he region of interest. Resources ﬂow in and out following chemo-
tat dynamics, that is, there is a constant inﬂow of medium with
esource concentration ˆ R , and the resource concentration of the
utﬂowing medium equals R . The inﬂow and the outﬂow have the
ame ﬂow speed λ, so that the volume of the resource medium
4 A.S. Halkola, K. Parvinen and H. Kasanen et al. / Journal of Theoretical Biology 488 (2020) 110136 
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m  in the region of interest remains constant. In the absence of con-
sumption, the resource concentration follows the differential equa-
tion dR 
dt 
= λ( ˆ  R − R ) ( Smith and Waltman, 1995 ). 
When the cancer cell density is low, cancer cells consume re-
sources according to the law of mass action ( Tóth and Érdi, 1989 ),
with the proliferation consumption rate α( s i ). It is assumed that
this rate is of the form 
α(s i ) = α0 + a 
s i /b 
1 + s i /b 
, (4)
which is an increasing function of s i with the upper limit of α0 + a .
The upper limit is given since cells cannot consume resources in-
ﬁnitely fast. Even if cancer cells would lack division regulation, the
cell cycle cannot happen inﬁnitely fast. Additionally, high cancer
cell density restricts resource consumption, for example, through
increasing the distance between veins ( Tannock, 1968 ). Therefore
the resource consumption rate α( s i ) is multiplied by the factor 
1 − w 
∑ 
j 
C j 
1 + ∑ 
j 
C j 
, (5)
which is a decreasing function of the total cancer cell density and
where w is the maximum proportion of restriction. The half satu-
ration is reached when the total cancer cell density is one. How-
ever, with the chosen parameter values, the maximum total can-
cer cell density is around 0.8 in all case studies investigated in
Section 3 due to other restrictions, such as the amount of inﬂow-
ing resources ( ˆ  R ), and thus the saturation 
∑ 
j 
C j 
(1+ ∑ 
j 
C j ) 
< 0 . 5 . 
The dynamics of cancer cells are determined by the balance be-
tween proliferation and apoptosis. It is assumed that cells attempt
division with a rate that is directly proportional to their resource
usage, with the conversion coeﬃcient γ : 
γα( ¯s C i ) 
⎛ 
⎝ 1 − w 
∑ 
j 
C j 
1 + ∑ 
j 
C j 
⎞ 
⎠ RC i . (6)
However, not all attempted divisions are successful. In the pres-
ence of a cytostatic drug, mitosis is interfered and the attempted
cell division results in the death of the dividing cell with a proba-
bility p i , which is further discussed in Section 2.3.3 . The division
proceeds with the probability of (1 − p i ) . Furthermore, the mi-
croenvironment of cancer is assumed to have a carrying capacity,
e.g., due to limitations of space, resulting in a variable likelihood
of a successful division 
1 −
∑ 
j 
C j 
K 
, (7)
which decreases with the total cancer cell density. 
Cancer cells of type i have a natural death rate μi , and targeted
drugs increase the death rate by β i , depending on sensitivity or re-
sistance of the cancer subpopulation to the drug. Modelling of the
treatment effects are discussed in more detail in Section 2.3.3 . Ad-
ditionally, active killer T-cells that enter the microenvironment of
cancer ( θT ) kill cancer cells with the subpopulation-speciﬁc rates
ξ i . If a cancer cell subpopulation i does not present the antigen
that T-cells are speciﬁc for, active killer T-cells do not recognize
the cells at all (ξi = 0) . 
2.3.2. Active killer T-cells 
When cancer cells face cell death, they deliver antigens to the
blood stream ( Chen and Mellman, 2013 ). The total rate at whichuch antigens are delivered is given by 
 C = 
∑ 
i 
(
μi + γα( ¯s i ) 
(
1 − w 
∑ 
C j 
1 + ∑ C j 
)
Rp i + βi + ξi θT 
)
C i , 
(8)
hich includes normal cancer cell death ( μi ), death by drugs
s well as death caused by active killer T-cells ( ξ i θT ). Here,
< 1 speciﬁes the proportion of delivered antigens by one nor-
al cancer cell apoptosis (poorly immunogenic), compared with
eath caused by drugs or killer T-cells (immunogenic cell death)
 Ferguson et al., 2011; Zhou et al., 2019 ). The delivery of antigens
eads to the activation of antigen-speciﬁc killer T-cells from naï T-
ells, so that killer T-cells are produced with the rate 
 (d C ) = m − m 
1 + (d C /u ) v 
, (9)
hich is an increasing function of antigen delivery rate d C , where
 is the maximum rate of killer T-cell activation and h (u ) = m/ 2
nd v affects the slope at u . Sigmoid function is chosen since
mall amount of antigen delivery might not be suﬃcient to in-
oke proper activation due to lack of a robust signal and complex-
ty of immune response ( Motz and Coukos, 2013 ). The amount of
aï T-cells is assumed to be large compared with the activation
ate h ( d C ), so that the amount of naï T-cells can be assumed to be
onstant and h ( d C ) is scaled accordingly. 
Active killer T-cells proliferate with the rate αT and they go
hrough normal cell death at the rate μT . Since killer T-cells do di-
ide, they are inhibited by cytostatic drugs with the rate p T , lead-
ng to restricted proliferation and increased cell death, which are
onsidered toxic side-effects. In contrast, targeted treatment is as-
umed not to affect T-cells directly but only trough increasing anti-
en delivery (8) by cancer cell death. Active killer T-cells circu-
ate in the body until they detect their target and inﬁltrate into
he tumor microenvironment ( Chen and Mellman, 2013 ). The pro-
ortion of active killer T-cells present in the microenvironment of
ancer is assumed to be constant θ for simplicity. These T-cells
T then proceed to kill cancer cells. However cancer cells use the
D-1/PD-L1 binding to make active killer T-cells ineffective, with
he subpopulation-speciﬁc intensities ϕi . If a cancer subpopulation
 does not have PD-L1, then ϕ i = 0 . The dynamics of the ineffec-
ive killer T-cells are not considered in the model. Immunotherapy,
uch as anti-PD-L1/anti-PD-1, is be used to prevent the binding of
D-1 and PD-L1 ( Chen et al., 2012 ), and this happens with the can-
er cell-type speciﬁc rate ρ i , as further discussed in Section 2.3.3 .
he immune system uses self-regulation to prevent overpopulation
f killer T-cells and autoimmune disease ( Disis, 2010 ), and this is
odeled as T-cells interacting with each other with the rate δ. 
.3.3. Treatment modelling 
The dose-response effect of a cytostatic drug with a concentra-
ion of c p ( τ ) is modeled using the Hill equation ( Gesztelyi et al.,
012 ): 
 p = H(c p (τ ) , IC50 p , n p ) = 1 − 1 
1 + (c p (τ ) /IC50 p ) n p , (10)
here IC 50 is the half-maximal inhibitory concentration and n , so
alled Hill coeﬃcient ( Gesztelyi et al., 2012 ), affects the slope of
he Hill function at the concentration IC 50. 
The activity of chemotherapy is based on the proliferation rates
f cells. For example, some nerve cells hardly divide, whereas most
ancer cells divide rapidly, making them more vulnerable to the
ytostatic drugs. However, there might be differences in the prolif-
ration rates between cancer cell subpopulations within the same
umor. Chemotherapy disrupts cell division by damaging bench-
arks in the cell cycle ( Malhotra and Perry, 2003 ). The more
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t  apidly dividing cell populations reach those benchmarks more of-
en, and therefore do not have time to repair, causing a cell death.
ytostatic drugs cause failure of division, followed by cell death,
ith the probability p i , and so division proceeds with the proba-
ility 1 − p i , where 
p i = p( ¯s i ) = 
s i 
1 + s i 
H(c p (τ ) , IC50 p , n p ) (11) 
ith the subscript p denoting the Hill parameters of the cytostatic
rug. In addition to the dose-response effect by Eq. (10) , the prob-
bility p i depends on the proliferation strategy s i , since the speed
f cell division affects the outcome of cytostatic treatment. 
Molecularly-targeted treatments often have less side-effects,
nd therefore their clinical use is warranted provided one can se-
ect treatments targeting the patient-speciﬁc cancer driver mu-
ations or other molecular targets. In case there are no effec-
ive drugs for a resistant cancer subpopulation, there is another
ay to control the resistant subpopulation by letting more rapidly
ividing, sensitive cancer cells dominate the resistant ones. The
ensitive cancer subpopulation is controlled by the treatment
 Zhang et al., 2017 ). Targeted therapy increases death rate by β i 
hich follows the Hill Eq. (12) . If the drug does not affect cell type
 , the rate βi = 0 , otherwise 
i = 1 −
1 
1 + (c β (τ ) /IC50 β ) n β
, (12) 
here the subscript β denotes the Hill parameters for the targeted
rug. 
In this model, cancer cells use PD-1/PD-L1 binding to disturb
he immune response, and hence anti-PD-L1/anti-PD-1 can be used
s immunotherapy. Immunotherapy reduces PD-1/PD-L1 binding
y the cancer cell subpopulation-speciﬁc intensity 
i = 
(c ρ (τ ) /EC50 ρ ) n ρ
1 + (c ρ (τ ) /EC50 ρ ) n ρ , (13) 
here EC 50 ρ is the concentration that produces half-maximal eﬃ-
acy and n ρ affects the slope at EC 50 ρ . When the drug concentra-
ion c ρ ( τ ) gets bigger, ρ i approaches 1. This is desired since ρi = 1
ould mean complete prevention of unwanted PD-1/PD-L1 binding
odeled by (1 − ρi ) C i θT . 
The treatment is given as an infusion at the beginning of a
reatment period, during which the drug concentration is assumed
o be a positive constant for simplicity. After the treatment pe-
iod the drug concentration is assumed to be zero. The length of
he treatment period is varied to consider the differences in drug
learance in the case of infusion. If the treatment is given as daily
osages, it is done only during the treatment period that deter-
ines for how long the daily dosages are given without a break
drug holiday). 
.4. Measures 
The following numeric measures are calculated from the model
ynamics. They are used to quantify and compare different situa-
ions in terms of medical outcomes. 
Treatment effect 
The treatment effect is monitored by cancer cell population
ean density, calculated as the integral of the amount of cancer
ell population over time divided by the length of the selected
ime period. Additionally, the maximum of total cancer cell density
 C max ) quantiﬁes the maximal tumor burden of the patient during
he given time interval. In some cases, the total cancer cell density
ecreases after reaching the C max . However, even a transient high
 max may be fatal to the patient. The methods to measure of total
ancer density or cancer burden depend on the cancer type. For
elanoma and many other solid tumors, changes in tumor burdenn the clinical evaluation of cancer therapeutics is typically mea-
ured with anatomical assessment of tumor volume or area using
maging technologies ( Dancey et al., 2008 ). 
Side-effects 
The side-effects are considered as the amount of T-cell loss
aused by cytostatic drugs, which is calculated as the proportion of
he amount of dead T-cells caused by cytostatic drugs to the over-
ll loss of T-cells (death or changing to ineﬃcient form because of
D-1/PD-L1 binding). The scaling is done so that levels of multiple
ituations can be compared with each other. 
Time in treatment 
Treatments cause also complications other than toxic effects on
he patient, such as time spent in hospital, which results in vari-
ble tolerability. Additionally, more treatment cycles usually means
ore drugs, leading to higher costs of treatment. To take such bur-
ens of treatment into consideration, we calculated the proportion
f time in treatment by dividing the total period of time spent in
reatment by the overall time interval. 
. Results 
We demonstrate the model dynamics using several case studies
hat correspond to virtual melanoma patients characterized by key
iological model parameters. We especially focus on modelling the
ersonalized effects of immunotherapies, such as pembrolizumab
r nivolumab, which are anti-PD-1 molecules with similar mode-
f-action. In clinical practice, nivolumab is given to patients every
nd week and pembrolizumab every 3rd week. However, the opti-
al timing and duration of these treatments is poorly understood
ither alone or in combination with other therapies, such as tar-
eted therapies (e.g. BRAF or C-KIT inhibitors) or chemotherapies
e.g. dacarbazine or temozolomide). Therefore, our case studies are
etermined by changing personal model parameters that affect
he dynamics of active killer T-cells and their competition against
ancer cell subpopulations, for example cancer cells’ effectiveness
gainst killer T-cells ( ϕi ) or maximum activation of killer T-cells
 m ) in an individual patient. Those parameters that are changed in
he case studies are marked with bold font in Table 1 , and their
alues are listed in Table 3 . Each case is started with cell densities
f 0.05 for all cell types. 
The majority of parameter values were obtained by testing if
umerical solutions are reasonable in comparison to the observed
linical outcomes in melanoma and other solid tumors ( Aguirre-
hiso, 2007; Ossowski and Aguirre-Ghiso, 2010; Schreiber et al.,
011; Senft and Ronai, 2016; Topalian et al., 2014; Wolner et al.,
018 ). Additionally, sensitivity analysis of the model parameters
as performed to identify those parameters having highest ef-
ect on the numerical solutions (see Section 3.6 and Supplemen-
ary section 8). The doubling times were calculated for melanoma
ells in each case study as explained in Supplementary section 3.
he doubling times were reasonable compared to experimental re-
ults in melanoma cells ( Laing et al., 2003 ). Killer T-cell parame-
ers were chosen so that small density is reached in the absence
f cancer cells if initial T-cell value is positive (some T-cells remain
n the system after defeating cancer). Additionally, the maximum
ate at which cancer cells limit each other’s resource consumption
 w ) multiplied by the saturation of cancer cells (maximum around
.44) was compared to observations of 4–56% relative volume of
ecrotic tissue in melanoma ( Tufto and Rofstad, 1998 ). 
As different cancer types share similar qualities, some of the
arameters are more generally related to cell functionality ( ˆ  R , λ,
, w and ), while others are speciﬁcally linked to cancer type,
ere melanoma ( α( s i ), μi , θ , ξ i and ϕi ). Parameters related to T-
ell dynamics ( αT , μT , m, u, v and δ) do not speciﬁcally concern
nly killer T-cells working against melanoma. Treatment parame-
ers ( c ( τ ) and Hill-parameters) are speciﬁc to a drug and its effect
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Table 3 
Parameters and their values that vary between case studies. Cancer doubling time presents the doubling time of 
cancer cells in total when no treatment is used (calculations in Supplementary Section 3). Calculated doubling 
times are close to median potential doubling time for melanoma cells of 8.6 days reported in experimental studies 
( Laing et al., 2003 ). 
Unit Fig. 2 a Fig. 2 b Fig. 2 c Fig. 3 Fig. 7 Fig. 8 
Parameter s C 1 – 1 1 1 1 1 1 
s C 2 – 0.95 0.95 0.95 – 0.95 0.95 
αT 1/(timeunit 
∗# T ) 0.505 0.505 0.267 0.505 0.505 0.505 
ξ 1,2 1/(timeunit 
∗# T ) 1.5 1.5 1.5 1.5 2 1.5 
ϕ1,2 1/(timeunit 
∗# C ) 5 1 1 3 4 3 
m # T /timeunit 0.5 0.5 1.5 0.5 0.5 0.5 
Treatment ρ1,2 – 0.999 – – 0.999 0.999 0.999 
β1 1/timeunit – – – – 0 –
β2 1/timeunit – – – – 0.432 –
c p ( τ ) mass/volume – – – – – 0 . 5 − 5 
IC 50 p mass/volume – – – – – 2 
n p – – – – – – 2 
Cancer doubling time in days 8 7 6 6 8 8 
Fig. 2. Three representative cases of dynamic competition between active killer T-cell (T) and cancer cell populations ( C 1 and C 2 ) at baseline (no treatment). Here one 
subpopulation ( C 1 ) divides faster and eventually dominates the less aggressive subpopulation ( C 2 ). The differences between subpopulations affect, for example, the treatment 
outcome, when the different cancer cell subpopulations (here C 1 and C 2 ) also have other undesirable qualities (e.g., treatment resistance, metastatic capabilities or promotion 
of angiogenesis). In real patient case, for example, formation of metastases would be more likely if the faster dividing subpopulation also has elevated metastatic capabilities. 
a) Active killer T-cells decrease without treatment, leading to fast increase of cancer cells toward a maximum level (here, 0.80). The maximum amount of cancer cells is 
restricted by carrying capacity of the cancer microenvironment as well as by the suﬃciency of resources. This baseline case is further investigated when treatment is given 
in Section 3.3 . b) The amount of active killer T-cells increases without treatment, leading to decreased amount of cancer cells. The cancer cell amounts alternate, but they 
are approaching a ﬁxed steady state, which reﬂects the case when the initial immune response is effective and cancer is not even detected. c) Whenever the amount of 
cancer cells try to increase, the active killer T-cells increase accordingly, but decreases steeply after cancer cell count has decreased. In this case, the density of killer T-cells 
and cancer cells approach a cyclic attractor that deﬁnes their balance in the absence of treatment or other intervention. All parameter values are listed in Tables 1 and 3 . 
Trajectories of b) and c) are presented in Supplementary Fig. 4. 
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a  on speciﬁc cancer type. Here the drug concentration is assumed
constant during the treatment period, therefore also the effect ( p i ,
β i or ρ i ) is constant. In addition to cancer speciﬁcity, some pa-
rameters are also considered patient speciﬁc as individuals have
different melanoma subtypes and different physiology. Ideally, all
parameters should be estimated individually, but in clinical prac-
tice this is still impossible and generally estimated values have to
be used. However, most important parameters that should be es-
timated individually are parameters that relate to the interactions
between cancer cells and T-cells ( ξ i and ϕi ). Additionally, the in-
ﬁltration of T-cells ( θ ) varies as some cancers modify the environ-
ment to block the T-cell inﬁltration, and cancer cells might even
inhibit the development of immune response in the ﬁrst place
( m = 0 )( Chen and Mellman, 2013 ). 
In the case studies, maximum of two cancer cell subpopulations
were included for simplicity (denoted by C 1 and C 2 ) to demon-
strate the model behavior when one subpopulation divides faster
than the other ( s C 1 > s C 2 ) . Additionally in the third case study
( Section 3.4 ), where targeted therapy is used, one subpopulation
was considered resistant ( β1 = 0 ) and the other sensitive ( β2 > 0)
to the targeted treatment. There could be also other differences be-
tween the cancer cell subpopulations, for example, one subpopu-
lation might not present the same antigen causing ineffectivenessf T-cells ( ξi = 0 ). However, these possibilities are not investigated
ere due to increased complexity. In the case studies, the concen-
ration of targeted therapy and immunotherapy are kept constant,
ence for β i and ρ i only the effect size is given instead of concen-
ration. 
.1. Baseline cases: no treatment 
We ﬁrst investigated selected patient cases without any treat-
ent (i.e. baseline cases). In some cases this means that cancer
ells will eventually dominate, resulting in a decreased amount of
ctive (and effective) killer T-cells in the body. Interestingly, chang-
ng the behavior of killer T-cells relative to that of cancer cells may
lso lead to cases where killer T-cells are able to control cancer
ells even without treatment. Some representative cases are pre-
ented in Fig. 2 , where the cell densities of the model are shown
s a function of time. 
Fig. 2 a presents a challenging case, where the amount of active
iller T-cells decreases monotonically and the total amount of can-
er cells increases to a maximum level. Notably, after around 40
ays, the cancer cell subpopulation C 2 also starts decreasing, since
he other cancer subpopulation C 1 proliferates more aggressively,
nd therefore starts to dominate also C . In this case, treatment2 
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Fig. 3. Single-shot immunotherapy. a) Immunotherapy is given for a period of 16 days (grey bar), started when the total amount of cancer cells exceeds a threshold of 0.5 
(dashed orange line). During the treatment, the drug concentration is assumed constant resulting in a constant treatment effect. In this case, the treatment almost completely 
prevents PD-1/PD-L1 binding and thus prevents cancer cells from making active killer T-cells ineffective ( ρ i ≈ 1). b) and c) Phase plane plots showing the isoclines (black 
lines) of the killer T-cell density T and cancer cell density C , b) during no treatment and c) during treatment. It is assumed that dynamics of resources are fast and in their 
stable state at each point. The trajectories shown with respect to time in panel a) are shown also in the phase plane plots (blue lines). The trajectory is plotted with a 
solid curve when the actual treatment status is the same as in the phase plane plot (treatment or no treatment). Red circle marks the ﬁxed attractor that would have been 
reached without treatment and this area is zoomed on the top right corner with blue line denoting the trajectory when no treatment is used. c) The corresponding phase 
plane when immunotherapy is used. Solid blue line corresponds to the trajectory during treatment while dashed blue line is the trajectory when no treatment is used. (For 
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.) 
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c  s needed, and different treatment options are further discussed in
ection 3.3 . 
Fig. 2 b presents a positive case, where active killer T-cells are
ore effective against cancer cells, whereas cancer cells’ PD-1/PD-
1 binding is expressed less than in Fig. 2 a. This results in a situ-
tion where active killer T-cells manage to control the cancer cells
ithout treatment, and their amounts ﬂuctuate and approach a
xed steady state (stable attractor). If the active killer T-cells prolif-
rate less often, while the T-cell activation is increased, the active
iller T-cells defeat cancer cells in each relapse attempt, resulting
n a cyclic attractor ( Fig. 2 c). Periodic behavior has been found both
n cancer ( Fortin and Mackey, 1999 ) and in the immune system
 Stark et al., 2007 ) so likely it is possible also in the competition
etween immune system and cancer cells. However, such cyclic be-
avior presents a phenomenon that is likely to take place in the
ery early phases of the disease, when immune system is still able
o control the growing tumor ( Dunn et al., 2004; O’Donnell et al.,
019 ). Thus the melanoma might not yet be diagnosed and treated
nd cyclic behavior may well have gone undetected so far in real
atient cases and clinical trials. 
These representative cases demonstrate how different values in
he key model parameters related to underlying biology result in
oth inter-patient and intra-tumor variation in disease progres-
ion, and inﬂuence the individual physiology and pathophysiology.
n some cases, the immune system deals with the cancer progres-
ion so early the cancer might not even be detected and diagnosed.
owever, some patients do need treatment, and how to tailor it to
he individual needs is investigated in the following sections. 
.2. Case study 1 – single-shot immunotherapy 
In the ﬁrst case study we investigate the effect of immunother-
py on the virtual melanoma patient presented in Supplementary
igure 5a without treatment. The dynamics without treatment are
imilar to Fig. 2 a, however only one cancer cell subpopulation is
onsidered in order to investigate the attractor landscape more
asily. To start treating the patient, an anti-PD-1 immunotherapy is
iven when the total amount of cancer cells exceeds a pre-deﬁned
hreshold (here, 0.5, a detection limit of a diagnostic test). Fig. 3 a
hows the case of this patient with one treatment period starting
t day 18 (gray bar). One treatment period of 16 days is already
nough in this case to increase the amount of active killer T-cells
o a level that suﬃces to control the cancer cells below the thresh-ld. Such a dormant cancer has been also reported in real patients
 Aguirre-Ghiso, 2007; Ossowski and Aguirre-Ghiso, 2010; Schreiber
t al., 2011; Senft and Ronai, 2016 ). Additionally, major pathologic
esponses after a single dose of anti-PD-1 were observed also in
eal patients ( Huang et al., 2019; Tokuyasu et al., 2019 ). 
From Fig. 3 a it can be seen that both the killer T-cells and can-
er cells start to approach a ﬁxed steady state that is different from
he steady state reached without treatment. To illustrate dynamics
ear the different attractors, we constructed phase plane diagrams
 Fig. 3 b and c). The two phase plane diagrams show how the given
reatment causes a change in the isoclines and the steady state
hanges from the red circle in Fig. 3 b to the intersection of black
ines in Fig. 3 c. During treatment the trajectory starts to reach the
ew attractor (solid blue line in Fig. 3 c). Once the treatment is
topped, the phase plane and attractors return to that of Fig. 3 b
nd the cell densities are located on the phase plane in such rela-
ion to attractors that the original attractor is unattainable; instead,
 better situation for the patient, with decreased cancer cell den-
ity and increased killer T-cell density, is reached. With insuﬃcient
reatment (too short duration or too small dosage), the cell popu-
ation dynamics end up to the original attractor, corresponding to
o treatment (red circle). 
This case study demonstrates how there may exist multiple at-
ractors, and the ones with smaller density of cancer cells could be
onsidered as more favorable for the patient. It is also evident that
ifferently behaving cells (e.g., more aggressive cancer cells or less
ffective killer T-cells) result in different phase planes and attrac-
or landscapes. Some steady states could be reached with only one
uﬃcient treatment period, whereas cyclic attractors are observed
hen repeated treatments are required, both indicating stable dis-
ases that are under control with the proper treatment. An absence
f an asymptotic trajectory (either ﬁxed or cyclic) indicates a pro-
ressive disease. In the following sections, the virtual patient cells
arbor more than one cancer population, which cause more com-
lex phase planes and model behavior. 
.3. Case study 2 – repeated immunotherapy 
Let us next consider another virtual patient, with such aggres-
ive cancer, consisting of two subpopulations, that cannot be sta-
ilized with single treatment period alone, but who requires re-
eated immunotherapy. At baseline, without any treatment, the
ell population densities of this patient are as in Fig. 2 a. Therapy
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i  is clearly needed, and it is considered to be given using two differ-
ent regimens, either pre-deﬁned or adaptive treatment initiation,
which are compared in the following subsections. 
3.3.1. Pre-set treatment periods versus threshold-based treatment 
initiation 
A widely-used treatment option is to pre-set treatment periods
with pre-set intervals (e.g. Fig. 4 a). The duration of treatment pe-
riod and the intervals between treatments (so-called drug holiday)
are changed to illustrate different schedule options for pre-set pe-
riods. It is observed from the mean density of total cancer cells,
as expected, that shorter treatment durations require shorter drug
holidays for an effective treatment outcome ( Fig. 4 c). The corre-
sponding mean densities of the killer T-cells ( Fig. 4 e) give similar
results as T-cell level does not increase if the drug holiday is too
long compared to the treatment period. 
Another, more adaptive option is to start treatment only when
the total cancer cell count (i.e., total tumor burden) exceeds a given
threshold, and then treat for a pre-set period until the total tumor
burden goes below the threshold (e.g. Fig. 4 b). One interesting ob-
servation is that a selected treatment threshold gives quite simi-
lar mean densities ( Fig. 4 d and f) regardless of the treatment pe-
riod, because shorter treatment periods are repeated if the cancer
cell count remains still over the threshold. As expected, the mean
density of total cancer cells increases when the threshold is in-
creased since higher cancer levels are allowed before the treatment
is started. 
A practical question is: which of these options, pre-set peri-
ods or threshold-based treatment initiation, should be chosen for a
given patient? Perhaps not surprisingly, the answer depends on the
parameters of the treatment regimen: the duration of the treat-
ment period, relative to the intervals between treatments, and the
chosen threshold level. By choosing speciﬁc combinations, either
one of the two regimens can result in a smaller mean density, and
hence better therapeutic effect. To give an example, where pre-
set periods results in a smaller total cancer mean density when
equally long treatment periods are chosen, red boxes are marked
in Fig. 4 c (pre-set periods) and in Fig. 4 d (threshold). On the other
hand, choosing of treatment combinations of the blue boxes of
Fig. 4 c and d results in smaller mean density for the threshold-
based regimen. These four cases are shown separately in Supple-
mentary Figure 6. 
Considering only the mean density as a measure of treatment
beneﬁt does not however give the whole truth, since it does not
take into account the overall time of treatment for the various reg-
imens. For example, choosing a long treatment period with short
gaps between repeats means that treatment is almost continuous.
Small treatment threshold value might also result in nearly con-
tinuous treatment. It can be seen from Fig. 5 , that the pre-set pe-
riod has to be chosen carefully in order to reach beneﬁcial results
(a population mean close to 0.8 means that the treatment fails).
On the other hand, successful treatment result can be reached also
without increasing the time in treatment (in the chosen time in-
terval), provided the relative timing of treatment period and drug
holiday is chosen based on the individual characteristics (blue dot-
ted line). When threshold-based treatment initiation is used, the
shorter treatment periods are repeated if necessary and this leads
to equal levels of overall treatment time ( Fig. 5 green symbols). 
Overall, using a threshold-based adaptive regimen results in a
successful treatment outcome (cancer is kept in control) more of-
ten, compared to pre-set periods, since the treatment is given as
long as needed, although it might mean longer continuous treat-
ment periods due to repeated periods. Drug holidays between the
treatments, if too long, can easily cause a relapse that short treat-
ment periods cannot overcome. In practice it is diﬃcult to deter-
mine the amount of cancer at each time point, especially if theancer is inside the tissues, therefore choosing the threshold-based
reatment initiation might not be applicable unless diagnostic tests
re improved. 
.3.2. Changing pre-set period of immunotherapy 
The previous section demonstrated that if the pre-set treatment
eriods are applied with too long gaps between treatments, the
reatment easily fails (i.e., cancer is not under control). On the
ther hand, it would be preferred to apply treatment as seldom
s possible to reduce side-effects and costs of treatment. To inves-
igate this trade-off, we next consider changing the pre-set treat-
ent period after starting the immunotherapy to test the effect
f having longer drug holiday between treatments. In Fig. 6 a, the
reatment schedule is changed successfully after three treatment
eriods (48 days), which enabled increased drug holiday from 6
ays to 16 days. Interestingly, whereas having such longer drug
oliday from the beginning would result in a rapid treatment fail-
re ( Figs. 4 c and 6 , and Supplementary Figure 6), starting with a
ighter schedule makes it later possible to increase the treatment
aps, provided those are chosen based on patient characteristics.
or instance, in Fig. 6 b, the new drug holiday is only slightly longer
20 days vs. 16 days), yet there is a marked increase in total cancer
ell density due to longer drug holidays, during which the amount
f killer T-cells decreases to a level from where the amount can-
ot recover any more, at least by the given treatment of 12 days.
n Fig. 6 c, the treatment schedule is changed later (after 102 days),
ut this also leads to a treatment failure in this patient case, in-
icating that scheduling of the ﬁrst treatment periods is critical
or determining whether or not the treatment could be given with
onger drug holidays later. 
As the treatment starts to fail when going from the case of
ig. 6 a to b and c, it is not surprising that the cancer cell maximum
nd mean density increase, as well as the tumor burden after one
ear (barplots on the right-hand side of Fig. 6 ). On the other hand,
he proportion of time in treatment is longer in the case of Fig. 6 a
han in the case of Fig. 6 b, since the treatment is given more of-
en (the barplots below the dynamics). When comparing the treat-
ent response of Fig. 6 a to that of Fig. 4 a (measures marked with
lue lines on Fig. 6 ) it is noticeable that the proportion of time
n treatment is smaller (due to a sparser treatment schedule), but
till resulting in similar cancer total density after one year. With
he heaviest treatment schedule of Fig. 4 a (12 days treatment, 6
ays drug holiday), the lowest mean population density is reached,
s expected, but this comes at the expense of time spend in treat-
ent. The practical question is: which one is more important for
he patient. If the treatments are not well-tolerated, then it might
e preferred to reduce the time in treatment, even if the tumor
urden stays on a slightly higher level. 
.4. Case study 3 – combination of targeted and immunotherapy 
In the previous sections, we investigated the virtual patients’
esponses to various regimens of immunotherapy only. In some
ases, however, it might be more beneﬁcial to combine the im-
unotherapy with targeted treatments, especially if it can be tar-
eted to the patient’s molecular aberrations, and in this way boost
he treatment responses. To make the situation more challenging,
e assume that the targeted treatment is effective against only
ne of the cancer cell subpopulations ( C 2 in this case), whereas
he other subpopulation is resistant to the targeted treatment. 
To study the potential beneﬁts of such personalized immune-
reatments, we treated the virtual patient with various strategies,
here the patient either receives immunotherapy alone ( Fig. 7 a),
hich resulted in a chronic disease with repeated treatment, or us-
ng a combination of targeted and immunotherapy ( Fig. 7 b and c).
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Fig. 4. Pre-set immunotherapy periods versus threshold-based treatment initiation. a) Pre-set period of 12 days of treatment followed by 6 days of drug holiday. b) Im- 
munotherapy is started when the total cancer cell density goes above the treatment threshold of 0.3, followed by 12 days period. Treatment is repeated at ﬁrst three times 
and later two times since the cancer cell density stays over the threshold. c) Mean density of total cancer cells for different treatment periods and drug holidays (marked 
with ∗ in panel a)). To give comparative examples, a few treatment options are marked with red or blue boxes. The red box corresponds to treatment period of 18 days, 
followed by a drug holiday of 18 days, with a mean population density of 0.20. In the blue box, the corresponding values are 8, 10 and 0.70. d) Mean density of total cancer 
cells for different treatment periods and thresholds of treatment initiation. The red box corresponds to treatment period of 18 days and threshold of 0.75, with a mean 
density of 0.49. In the blue box, the corresponding values are 8, 0.2 and 0.19. e) Mean population density of active killer T-cells in the case of pre-set treatment period, and 
f) in the case of threshold-based regimen. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.) 
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m  Both of the treatments were initiated simultaneously, for simplic-
ity, but their durations differ so that the combined treatment dura-
tion is always set to 14 days and its division to the two treatment
options is varied. When both of the treatments have the same du-
ration of 7 days ( Fig. 7 b), the treatment has to be repeated, due to
rapid decrease in the amount of killer T-cells, and eventually only
the resistant cancer subpopulation C 1 stays alive, and the targeted
treatment becomes useless. In contrast, when changing the dura-
tions of the treatment periods, it is possible to come up with more
effective modalities in which the chosen drug combination leads to
a situation where no further treatment is needed in order to keep
the cancer density below the treatment threshold of 0.5 ( Fig. 7 c).
This is because after the second treatment period, the densities of
cancer cells and killer T-cells trajectories reach a suitable balance
that leads to a better attractor for the patient (in similar fashion as
in Section 3.2 ). 
To investigate these situations more systematically, the total
cancer mean densities are calculated when the treatment threshold
is varied with the proportion of targeted treatment ( Fig. 7 d). Ad-
ditionally, to investigate the trade-off between therapy effect and
therapy intensity, the corresponding numbers of treatment initia-
tion are calculated ( Fig. 7 e). One can see that with most treatment
proportion combinations, smaller threshold leads to smaller cancer
mean densities, but that also requires more treatment periods. Im-
munotherapy works by itself (0% of targeted therapy) but adding
a small proportion of targeted therapy decreases total cancer cell
mean density, while with most of the treatment thresholds, equal
number of treatment initiations is needed. 
Our model also predicts in this case study that combination
therapy works better than targeted therapy alone. When only tar-
geted treatment is used, if treatment is initiated too early (thresh-
old ≤ 0.1), total cancer cell density increases rapidly to maximum
value due to the targeted treatment being effective only on one
cancer subpopulation, which decreases rapidly and only the resis-
tant subpopulation remains. Since there is not enough sensitive
cancer cells to deliver antigens in the ﬁrst place, the density of
T-cells does not increase suﬃciently to dominate the resistant can-
cer subpopulation ( C 1 ). However, if the treatment is initiated too
late (threshold ≥ 0.31), the treatment succeeds once, followed by
relapse, since by the time of the second treatment initiation, the
density of the sensitive cancer subpopulation ( C 2 ) has fallen too
low, and the targeted therapy does not have enough effect to in-
crease the level of killer T-cells. 
Interestingly, if the treatment threshold is around 0.15–0.3 in
this case, the targeted treatment is effective also on its own with-
out immunotherapy (when considering the total time interval of
160 days). For well selected treatment thresholds (e.g., 0.3) only
four treatment initiations are needed, leading to similar stable dis-
ease as in Fig. 7 c. This surprising result is due to such optimalreatment initiation and period for this patient case that drive the
ancer cell densities on the attractor landscape in a region which
eads to a ﬁxed steady state after the treatment. It should be noted
hat even though the combination treatment might result in some
ases in a smaller tumor burden (cancer cell mean density), it may
ot be still beneﬁcial from the treatment tolerability (and cost)
oint of view, when considering the total amount of drugs used,
ince each treatment period includes two (expensive) drugs in-
tead of one. In an optimal and cost-effective therapy regimen, the
mount of treatments needed should be minimized to compen-
ate for the costs, along with possible tolerability issues caused by
dding more treatments. 
.5. Case study 4 – combination of chemotherapy and 
mmunotherapy 
In the ﬁnal case study, we consider a situation where a virtual
atient does not have any targeted therapies matching to his/her
ancer aberrations ( C 1 or C 2 ) and who, without treatment, would
ave rapid increase in the total cancer cell density (Supplementary
ig. 5c). Therefore, chemotherapy is the only option, used either
lone (e.g. Fig. 8 a) or in combination with immunotherapy (e.g.
ig. 8 b). Since cytostatic drugs cause side-effects, their minimal use
s preferred with small concentrations. 
When changing the treatment period and concentration of the
ytostatic drug, the proportion of time in treatment decreased in
lmost every case, when comparing the combination treatment to
hemotherapy alone ( Fig. 8 c, green shapes appear on the left side
f the corresponding blue shapes). This indicates that adding the
mmunotherapy decreases the treatment time with additional pos-
ibility of smaller cancer cell mean density ( Fig. 8 c, green shapes
ppear below or on similar level to the corresponding blue shapes).
The side-effects in this case are calculated as the proportion
f T-cell loss caused by cytostatic drug to the overall T-cell loss,
nd they are investigated along with therapeutic effect (total can-
er cell mean density) in Fig. 8 d across various treatment peri-
ds. When the combination of chemotherapy and immunotherapy
s used and the treatment period is short (4 days), the side-effects
re less than the side-effects caused by chemotherapy alone. How-
ver, when the treatment period is increased (20 days) the com-
ination therapy causes slightly more side-effects than mono-
hemotherapy, because the longer period of immunotherapy de-
reases more the overall loss of T-cells by preventing the PD-1/PD-
1 binding, and hence the proportion of T-cell loss caused by cyto-
tatic drug increases. 
The combination therapy leads to smaller or similar cancer pop-
lation mean densities compared to chemotherapy alone, but the
ifferences are not so dramatic that it would be clear which treat-
ent regimen to choose only by looking at the cancer cell mean
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t  ensity or proportion of T-cell loss caused by chemotherapy. Addi-
ional considerations in practice involve the trade-off between the
se of two treatments simultaneously or potential treatment toler-
bility issues caused by immunotherapy. 
.6. Sensitivity analysis 
To investigate how sensitive the results are to the changes in
he model parameters, we perturbed the underlying biological pa-ameter values that remained constant in the virtual melanoma
atients (increased and decreased 25% from their values listed in
able 1 ). It was observed, generally, that increasing ˆ R , K, γ or λ
ed to increases in the maximum cancer cell density, as expected,
hereas decreasing these parameters reduced the maximum can-
er cell density accordingly ( Table 4 ). Similarly, increases in the re-
ource competition between the cancer cell populations w reduced
he maximum cancer cell density, and vice versa. Under treatment,
hese general conclusions remain the same. However, the cancer
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Fig. 7. Combined effect of targeted and immunotherapy. a) Immunotherapy with period of 14 is initiated when the total cancer cell density goes over the treatment threshold 
of 0.4. b) Immunotherapy period of 7 days is given with simultaneous 7 days period of targeted treatment that is effective against the cancer cell subpopulation C 2 . 
c) Targeted therapy period of 10 days combined with simultaneous immunotherapy period of 4 days. d) Total cancer cell population mean density when the treatment 
threshold and division of treatment durations is changed. The combined treatment time is ﬁxed to 14 days, and hence the durations of targeted and immunotherapy can be 
calculated from the proportion of targeted therapy. For example proportion of 50% targeted treatment means 7 days of targeted treatment in combination with 7 days of 
simultaneous immunotherapy. e) The corresponding numbers of treatment initiations. 
Table 4 
The change percentages of killer T-cell mean density, maximum T-cell density, cancer cell mean density and maximum 
cancer cell density on average over all case studies and treatment options. Parameter values are increased ( ↑ ) or 
decreased ( ↓ ) 25% from their value listed in Table 1 . Only one parameter value is changed at a time, while others are 
kept constant. Mean dens. denotes mean density. 
Without treatment With treatment 
Change T mean dens. T max C mean dens. C max T mean dens. T max C mean dens. C max 
ˆ R ↑ +11% 0% +43% +42% +224% +79% −1% +15% 
ˆ R ↓ 0% 0% −45% −44% −73% −58% +20% −20% 
K ↑ +1% 0% +4% +4% +6% +3% 0% +1% 
K ↓ −2% 0% −6% −6% −11% −7% +4% −2% 
γ↑ +9% 0% +44% +42% +225% +78% −1% +14% 
γ↓ +5% 0% −45% −44% −73% −58% +20% −19% 
δ↑ 0% 0% 0% 0% −10% −8% +6% +1% 
δ↓ 0% 0% 0% 0% +7% +6% −7% −1% 
θ↑ −14% 0% 0% 0% +2% +9% −9% 0% 
θ↓ +22% 0% 0% 0% +17% −2% +18% +4% 
w ↑ −3% 0% −13% −13% −23% −15% +10% −4% 
w ↓ +4% 0% +14% +14% +45% +20% −4% +4% 
λ↑ +3% 0% +11% +11% +631% +173% −9% +1% 
λ↓ −3% 0% −14% −14% +401% +107% +6% −5% 
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o  cell mean density did not behave similarly with and without treat-
ment. As the cancer cell density increased faster, the T-cell den-
sity was affected as well, and accordingly the treatment succeeded
more often with the treatment options that caused failure with the
original parameter value. On the other hand, if the total cancer cell
level decreased below the speciﬁed treatment threshold, the treat-
ment was naturally not initiated at all leading to decreased killer-cell mean density and increased cancer cell mean density. For
xample, the effect of changing ˆ R on total cancer cell mean den-
ity in the case study 2 ( Section 3.3 ) is shown in Supplementary
igure 9. The sensitivity analysis shows that increasing the killer
-cell self-regulation parameter δ reduced the killer T-cell levels,
s expected, and decreasing δ had the opposite effect, with neither
ne changing the general conclusions made about the treatment
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v  ﬃcacy. Since θ affects many interactions in the model (T-cell acti-
ation and interactions between cancer cells and T-cells), changing
t had treatment sensitizing effects. Systematic sensitivity analyses
re detailed in Supplementary Section 8. 
Analysis of steady states was performed in the case study 1
ith more parameters and larger change ranges (Supplementary
ection 8.1.1). It was observed, for instance, that when the rate at
hich cancer cells make active killer T-cells ineffective ( ϕ) is be-
ween 1.40 and 3.42, two stable steady states exist (grey bar in
ig. 9 ), and it is possible to move from one attractor to the other0 1 2 3 4 5
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ig. 9. Steady states of cancer cells (C) and killer T-cells (T) as the value of ϕ is 
hanged and other parameters are kept constant as in the case study 1. The grey 
ar denotes the range where two stable steady states exist. 
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F  ith carefully scheduled treatment (e.g., one used in Fig. 3 ). In
he case study 1, ϕ = 3 , and the attractor is changed after single-
hot immunotherapy (see Fig. 3 ). However, when the rate is high
3.42 ≤ ϕ ≤ 5), only a single stable steady state exists with rel-
tively high cancer cell density. In this case, the cancer cell den-
ity returns to that level even if it is temporarily decreased during
reatment. When the rate is small (0 ≤ ϕ ≤ 1.40), only one sta-
le steady state exists as well. However, the cancer cell density is
lready relatively low and depending of the treatment threshold
alue, the treatment might not be initiated at all. For all investi-
ated parameters, it is important to identify, in which parameter
alue range there are more than one stable steady state (attractor
an be changed with treatment), and, in the case of single stable
teady state, if the cancer cell density is high (treatment is only
emporary solution) or already relatively low (treatment might not
e necessary). Steady states for cancer cells and T-cells were calcu-
ated with R-script grind.R ( http://tbb.bio.uu.nl/rdb/grindR/grind.R ).
As the dynamics of cancer and immune system are complex, it
s not surprising that the outcome of treatment is sensitive to ex-
ct rates of interactions. Ideally, all parameters are patient-speciﬁc,
nd should be measured from individual patients. However, this
s not yet realistic in clinical practice and parameter values esti-
ated from cell lines or in general population have to be used. In-
ividually, the most important parameters are the interactions be-
ween cancer cells and T-cells. For example, if the rate at which
-cells kill cancer cells ( ξ i ) is too low ( ≤ 1.34 in the case study
), only a single stable steady state exists and treatment can only
emporarily decrease the cancer cell density (see Supplementary
ig. 8k). Similarly, the inﬁltration of T-cells into the microenviron-
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vment of cancer depends on the individual’s physiology. If T-cells
cannot inﬁltrate the microenvironment of cancer ( θ = 0 ), the pos-
sible effect of treatment is only temporary since the only stable
steady state for cancer density is relatively high. Additionally, the
cancer cells might inhibit the immune response (e.g., CTLA4), lead-
ing to decreased or non-existent activation of killer T-cells ( m = 0 ).
The maximum rate of T-cell activation ( m ) should be high enough
( ≥ 0.45 in the case study 1) that a stable steady state with lower
cancer cell density exists (see Supplementary Fig. 8i). Luckily, there
are therapies (e.g., anti-CTLA4), that may help patients with inhib-
ited immune response ( Chen and Mellman, 2013 ). 
4. Discussion 
We have developed a comprehensive model for the dynamics
of active killer T-cells and their competition against distinct can-
cer cell populations under various treatment modalities. To our
knowledge, this is the ﬁrst mathematical model that incorporates
all the key aspects required for studying the individualized effects
of anti-PD-1 immunotherapies in combination with targeted and
chemotherapies, in terms of both therapeutic and side-effects. Im-
portantly, rather than using the traditional approach that deﬁnes
the cancer cell populations based on their genetic makeup alone,
we consider also other, non-genetic differences that make the cell
populations either sensitive or resistant to a therapy. Our model
can be easily tailored to different scenarios, consisting of individual
patients and treatment regimens. Here, we showed how the model
provides insights into immunotherapy when comparing pre-set pe-
riod treatment to more ﬂexible threshold-based treatment initia-
tion. It was noted that pre-set periods have to be chosen carefully
in order to receive positive outcome. Interestingly, starting with
tighter treatment schedule (shorter drug holidays) may enable a
sparser treatment schedule later on. Additionally combination of
targeted and immunotherapy was investigated, which results in a
better treatment effect (cancer cell mean density) with fewer treat-
ment initiations if used in suitable relation to each other. A stable
disease might be also reached with few treatment initiations us-
ing combination therapy or targeted mono-therapy with carefully
chosen treatment thresholds. Similar results were seen when using
combination of chemotherapy and immunotherapy in comparison
to chemotherapy alone. Combination results in smaller or equal
level of cancer mean density and treatment times. 
Systematic analysis of the effects of the various treatment
choices was investigated through measures that capture the ther-
apeutic beneﬁt and toxic side-effects of the considered regimens.
For example, tumor burden, measured as population mean of can-
cer cells, and time spend on treatment, both for immuno- and
other therapies, quantify the eﬃcacy of the treatment and the pos-
sible stress it causes to the patient and expenses to the health care
operator, respectively. However, the eventual success of a treat-
ment regimen is often determined by a subtle trade-off between
the therapy-driven tumor burden reduction and toxic side-effects,
as a function of the treatment intensity (so-called therapeutic win-
dow). Since there are individual differences in how patients expe-
rience both the therapy and its side-effects, the preferred treat-
ment regimen that maximizes the tumor reduction might not be
tolerated in clinical practice. Therefore, it is important to consider
these different measures of treatment responses when deciding
optimal regimens for a given patient. Previous model-based stud-
ies have also demonstrated the importance of high-resolution, dy-
namic monitoring of the cancer populations to achieve a given ob-
jective (e.g. adaptive treatment or cancer control) ( Fassoni et al.,
2019; Fischer et al., 2015; Khan et al., 2018; Komarova et al., 2014;
Lai et al., 2019; Zhang et al., 2017 ). 
In addition to the individual differences, the complexity of can-
cer and human biology poses challenges to the treatment re-ponse modelling. In the future work, it would be interesting to
nclude, for example, the effect from disrupted angiogenesis (re-
istance to anti-angiogenic therapy ( Bergers and Hanahan, 2008 ),
volution of angiogenic potential in cancer cells ( Nagy and Arm-
ruster, 2012 ), adaptation to low level of resources, quiescent
ells (trade-off of proliferation speed and adaptation to stress-
ul conditions ( Aktipis et al., 2013 ), or delay in the response to
mmunotherapy. Furthermore, the emergence of new mutations
r other molecular aberrations will be important to consider for
odelling clonal evolution, since the relapse is often caused by
ew resistant clones that occur either due to cancer evolution
r in response to chemotherapies ( Gerlinger and Swanton, 2010;
ozłowska et al., 2018 ). In the present work, we considered two
ancer subpopulations (sensitive and resistant), but the model can
e extended to multiple dynamically-adapting populations, once
he underlying rules of clonal evaluation are speciﬁed. 
In the current model, it was assumed that cancer cells make
ctive killer T-cells ineffective with PD-1/PD-L1 binding and that
he ineffective T-cells exit the system without possibility to be-
ome effective. However, some drugs are able to cancel the PD-1
ctivation and render the ineffective killer T-cells effective again
 Sakuishi et al., 2011 ). This re-activation effect could be consid-
red as an additional component in the current model, as well as
odelling different mechanisms of immunotherapies (e.g., CTLA4)
r differing targeted therapies (e.g., those having direct positive
r negative effect on T-cells, or those helping T-cells to enter into
he microenvironment ( Chen and Mellman, 2013 ). Additionally, dif-
erent combination treatment regimens could be considered, for
xample chemotherapy and immunotherapy given separately in
ub-sequent time periods. Furthermore, the amount of T-cells and
heir functionality does not go hand in hand, meaning that higher
mount of T-cells does not necessarily mean more eﬃcacy against
ancer, which could be considered in further investigations. Sim-
larly, adding various types of immune cells, including regulatory
-cells or natural killer cells, would more faithfully model the real
mmune-system component. 
In order not to make it overly complicated, the current model
acks many aspects of cancer and immune response, some of
hich are mentioned above. Multiple parameters (e.g., inﬂow of
esources, drug concentration) are thought as constants for sim-
licity, while in real patient these parameters change in time or
ver the disease progression. Even though adding more aspects
nto the model will make it more realistic, it also poses challenges
o its analysis and estimation with limited data. Our aim in this
ork was therefore to model only those aspects we deem most im-
ortant for the dynamic competition between active killer T-cells
nd cancer cell populations under the selected treatment modali-
ies. To widen the potential applications of the model, one of our
uture aims is to make use of laboratory measurements in can-
er cell line co-cultures, under selected treatment options, to ﬁt
he most critical model parameters with real-world measurements,
nd to evaluate the model qualitative behavior against that seen in
he laboratory experiments. Eventually, with better estimated pa-
ameters, the model could be used to predict the effectiveness and
onsequences of various treatment choices as well the occurrence
nd timing of cancer relapse. We hope this will lead to more re-
listic set-up for tailoring treatment choices for individual cancer
atients based on careful proﬁling of their primary tumor samples.
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